Argenica Assembles World-Class Stroke Experts to Shape Its Phase 2b Trial Design
Argenica assembles world-class advisory committee to drive ARG-007 Phase 2b trial design
Argenica Therapeutics (ASX: AGN), a clinical-stage biotechnology company developing neuroprotective treatments for acute ischaemic stroke, has established a Clinical Advisory Committee (CAC) specifically to advance the Phase 2b trial of its lead drug candidate, ARG-007. The CAC brings together internationally recognised specialists across stroke neurology, neuroimaging, neurointervention, and clinical trial design. Its formation marks a meaningful step forward in Argenica’s preparation for a rigorous, later-stage clinical programme.
When big ASX news breaks, our subscribers know first
Why the CAC matters for ARG-007’s path to Phase 2b
What a Clinical Advisory Committee does in drug development
A Clinical Advisory Committee is an independent group of external experts convened to advise on trial design, not to conduct the trial itself. In this context, the CAC’s specific remit covers optimising endpoints, patient selection strategy, and dosing approach for the planned Phase 2b study of ARG-007 in acute ischaemic stroke (AIS).
For investors, the formation of a CAC at this stage is a de-risking signal. It indicates the company is actively and methodically preparing for a later-stage clinical study, incorporating external expertise before committing to a final protocol. This type of structured preparation is consistent with what regulators and the broader clinical community expect from a well-governed drug development programme.
Why trial design expertise is critical in neuroprotection
Neuroprotection trials have historically faced significant challenges in both patient selection and endpoint design, contributing to a difficult development history in the field. ARG-007 targets AIS, where treatment windows are narrow and imaging-based identification of eligible patients is a key variable in trial outcome.
The CAC’s composition spans stroke neurology, interventional neuroradiology, neuroimaging, neuroprotectant drug development, and consumer representation. This breadth is deliberate, reflecting the complexity of designing a study with a realistic probability of clinical success rather than simply satisfying regulatory minimums.
Meet the Clinical Advisory Committee
The six-member committee covers the full spectrum of expertise required to optimise ARG-007’s Phase 2b design. Dr Mark Etherton, Argenica’s Non-Executive Director, Former Director of the Massachusetts General Hospital Acute Stroke Service, and Senior Medical Director at Takeda Pharmaceuticals, will provide additional support to the CAC through his extensive background in stroke and neuroprotection trials and clinical drug development.
| Name | Institution / Affiliation | Area of Expertise | Key Credential Relevant to ARG-007 |
|---|---|---|---|
| Prof Geoffrey Donnan | University of Melbourne / Australian Stroke Alliance | Stroke neurology, imaging-based patient selection | Former President, World Stroke Organization; global leadership in large-scale stroke trials |
| Dr Tim Phillips | Sir Charles Gairdner / Fiona Stanley / Royal Perth Hospitals | Interventional neuroradiology, reperfusion therapies | Principal Investigator on 11 active clinical trials; leads highest-volume interventional neuroradiology service in Australia |
| Prof Jeffrey Saver | UCLA Stroke Center | Acute stroke treatment, neuroprotection, EVT, trial design | Director, UCLA Stroke Center; major AIS trial leadership including neuroprotection and patient selection |
| Dr Michael Devlin | Princess Alexandra Hospital, Brisbane | Acute stroke management, imaging-selected trials | Principal investigator experience in Phase 2 trial and large vessel occlusion trials |
| Dr Taylor Kimberly | Mass General Brigham / Harvard Medical School | Stroke imaging, biomarker development, patient stratification | Co-principal investigator in late-stage trials of a neuroprotectant in large hemispheric infarction |
| Mr Tony Rolfe | Consumer representative | Health policy, research ethics, consumer engagement | Over 40 years in Australian health and research systems; lived stroke experience; Stroke Foundation Consumer Council |
The next major ASX story will hit our subscribers first
Management commentary and what comes next
Argenica’s Managing Director, Dr Liz Dallimore, framed the CAC’s establishment as a direct enabler of the company’s Phase 2b objectives.
Dr Liz Dallimore, Managing Director
“The appointment of this Clinical Advisory Committee represents an important step in advancing ARG-007 into a Phase 2b clinical trial. The Committee brings deep expertise in moderate-to-severe stroke, imaging-based patient selection and late-stage clinical development, which will be critical in optimising trial design and execution. We are focused on maximising the probability of success as we progress ARG-007 towards the next stage of development.”
The CAC’s work feeds directly into the finalisation of the Phase 2b study protocol. Its collective input will shape three specific design elements: endpoint selection, patient selection criteria, and dosing strategy. These decisions are among the most consequential in determining whether a later-stage trial generates statistically meaningful and clinically relevant results.
Key points from the update include:
- ARG-007 is Argenica’s lead drug candidate targeting neuroprotection in acute ischaemic stroke
- The CAC is now in place to optimise Phase 2b trial design
- The committee’s focus areas encompass endpoints, patient selection, and dosing strategy
- Phase 2b represents the next major clinical milestone in ARG-007’s development pathway
Don’t Miss the Next ASX Biotech Breakthrough
Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 active subscribers already rely on it to stay ahead of the market. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.